Full Indications

U.S. Healthcare Professionals

Real Patients Tell
Their Stories

Every patient or family member has a story to tell. The videos below feature real patients, caregivers, and family members who describe their experiences on an OPDIVO® treatment.

John’s Story

Click to watch John's experience with OPDIVO® (nivolumab)

OPDIVO for People Who Have Had Prior Treatments for Non-Small Cell Lung Cancer

John is a husband, father of two, and a passionate golfer. Learn more about his experience with OPDIVO. (13:56)

Click here to watch John’s story

For more information, see OPDIVO NSCLC clinical trial results.

Dave’s Story

Click to watch Dave's experience with OPDIVO® (nivolumab)

OPDIVO® + YERVOY® (ipilimumab) for Newly Diagnosed Advanced Melanoma

Dave is a restaurant owner and father. Three different doctors agreed that OPDIVO + YERVOY was the right choice for him. (17:44)

Click here to watch Dave’s story

For more information, see OPDIVO + YERVOY metastatic melanoma clinical trial results.

CAROL'S STORY

Click to watch Carol's experience with OPDIVO® (nivolumab)

OPDIVO + YERVOY for Certain Newly Diagnosed People With Advanced Kidney Cancer

After Carol was diagnosed, a doctor in her hospital was very involved in immunotherapy. Learn more about her treatment with OPDIVO + YERVOY. (17:58)

Click here to watch Carol’s story

For more information, see OPDIVO + YERVOY RCC clinical trial results.

Philip and Susan’s Story

Click to watch Philip's and Susan's experience with OPDIVO® (nivolumab)

OPDIVO for Previously Treated People With Advanced Kidney Cancer

Philip's cancer came back after receiving surgery. See how his wife Susan supported him during his treatment with OPDIVO. (12:02)

Click here to watch Philip and Susan’s story

For more information, see OPDIVO RCC clinical trial results.

Terry’s Story

Click to watch Terry's experience with OPDIVO® (nivolumab)

OPDIVO for People With Previously Treated Squamous Cell Carcinoma of the Head and Neck

Terry’s cancer kept returning with radiation and a platinum-based therapy. Learn more about his treatment with OPDIVO. (11:50)

Click here to watch Terry’s story

For more information, see OPDIVO SCCHN clinical trial results.

Nina’s Story

Click to watch Nina's experience with OPDIVO® (nivolumab)

OPDIVO for People With Previously Treated Advanced Small Cell Lung Cancer

Nina tried chemotherapy and radiation but her tumors kept growing. Learn about her experience when she started OPDIVO. (12:20)

Click here to watch Nina's story

For more information, see OPDIVO SCLC clinical trial results.

Would you like to share your story?

If you or a loved one is interested in sharing your experience on an OPDIVO treatment, please call
.

All patients were compensated for their time in the creation of these videos.

SIGN UP FOR

OPDIVO® with You Program

Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.

Sign Up Now
Watch this video to learn more about the OPDIVO with You program

Watch this video to learn more about the OPDIVO with You Program.

Getting an Infusion
Patient Resources

FULL INDICATIONS

For people with previously treated advanced non-small cell lung cancer

OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

For people with previously treated advanced small cell lung cancer

OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of advanced stage lung cancer (called small cell lung cancer) that has spread or grown and you have tried at least two different types of chemotherapy, including one that contains platinum, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For people with advanced melanoma

OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For people with melanoma after it and the affected lymph nodes have been removed by surgery to prevent it from coming back

OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

For certain people with advanced kidney cancer (renal cell carcinoma)

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat kidney cancer (renal cell carcinoma) in certain people when their cancer has spread.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For people with previously treated advanced kidney cancer (renal cell carcinoma)

OPDIVO® (nivolumab) is a prescription medicine used to treat people with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.

For people with previously treated squamous cell carcinoma of the head and neck

OPDIVO® (nivolumab) is a prescription medicine used to treat people with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.

For people with liver cancer (hepatocellular carcinoma) that have received treatment with Nexavar® (sorafenib)

OPDIVO® (nivolumab) is a prescription medicine used to treat people with liver cancer (hepatocellular carcinoma) after you have received treatment with Nexavar® (sorafenib). OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For people with previously treated advanced bladder cancer (urothelial carcinoma)

OPDIVO® (nivolumab) is a prescription medicine used to treat people with bladder cancer (urothelial carcinoma) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For people 12 years of age and older whose CRC has spread to other parts of the body (metastatic), has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and is dMMR or MSI-H

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older, with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For adults with previously treated classical Hodgkin lymphoma including an autologous stem cell transplant whose cancer has come back or spread

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the drug brentuximab vedotin (Adcetris®) before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer, or in children younger than 18 years of age for the treatment of any other cancers.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

Important Facts About OPDIVO® (nivolumab) and OPDIVO + YERVOY® (ipilimumab)

This is a summary of important information that you need to know about OPDIVO and OPDIVO + YERVOY. Your healthcare team can work with you to help answer any questions you may have about these medications. Keep this information in a safe place so you can refer to it before and during your treatment.

Look out for the following icons as you read:

  • Talk to your
    healthcare team
  • Call a healthcare
    provider right away
  • Helpful information
    to remember

What are the serious side effects?

A serious side effect is a side effect that can sometimes become life-threatening and can lead to death. They may happen anytime during treatment or even after your treatment has ended.

OPDIVO is a medicine that may treat certain cancers by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. Some of these problems may happen more often when OPDIVO is used in combination with YERVOY.

YERVOY can also cause serious side effects in many parts of your body which can lead to death. These problems may happen anytime during treatment with YERVOY or after you have completed treatment.

Get medical help immediately if you develop any of these symptoms or they get worse. It may keep these problems from becoming more serious. Your healthcare team will check you for side effects during treatment and may treat you with corticosteroid or hormone replacement medicines. If you have a serious side effect, your healthcare team may also need to delay or completely stop your treatment.

What are the serious side effects of OPDIVO and OPDIVO + YERVOY?

Lung problems (pneumonitis) — Things to look out for may include:

  • new or worsening cough
  • chest pain
  • shortness of breath

Intestinal problems (colitis) that can lead to tears or holes in your intestine — Things to look out for may include:

  • diarrhea (loose stools) or more bowel movements than usual
  • blood in your stools or dark, tarry, sticky stools
  • severe stomach area (abdomen) pain or tenderness

Liver problems (hepatitis) — Things to look out for may include:

  • yellowing of your skin or the whites of your eyes
  • severe nausea or vomiting
  • pain on the right side of your stomach area (abdomen)
  • drowsiness
  • dark urine (tea colored)
  • bleeding or bruising more easily than normal
  • feeling less hungry than usual
  • decreased energy

Hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas) — Things to look out for may include:

  • headaches that will not go away or unusual headaches
  • extreme tiredness
  • weight gain or weight loss
  • dizziness or fainting
  • changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
  • hair loss
  • feeling cold
  • constipation
  • voice gets deeper
  • excessive thirst or lots of urine

Kidney problems, including nephritis and kidney failure — Things to look out for may include:

  • decrease in the amount of urine
  • blood in your urine
  • swelling in your ankles
  • loss of appetite

Skin problems — Things to look out for may include:

  • rash
  • itching
  • skin blistering
  • ulcers in the mouth or other
    mucous membranes

Inflammation of the brain (encephalitis) — Things to look out for may include:

  • headache
  • fever
  • tiredness or weakness
  • confusion
  • memory problems
  • sleepiness
  • seeing or hearing things that are not really there (hallucinations)
  • seizures
  • stiff neck

Problems in other organs — Things to look out for may include:

  • changes in eyesight
  • severe or persistent muscle or joint pains
  • severe muscle weakness
  • chest pain

Additional serious side effects observed during a separate study of YERVOY alone include:

Nerve problems that can lead to paralysis — Things to look out for may include:

  • unusual weakness of legs, arms, or face
  • numbness or tingling in hands or feet

Eye problems — Things to look out for may include:

  • blurry vision, double vision, or other vision problems
  • eye pain or redness

OPDIVO can cause serious side effects, including:

Severe infusion reactions — Things to look out for may include:

  • chills or shaking
  • itching or rash
  • flushing
  • difficulty breathing
  • dizziness
  • fever
  • feeling like passing out

Talk to your healthcare team right away if you get any of the symptoms of a severe infusion reaction during or after an infusion of OPDIVO.

Stem cell transplant complications are possible if you receive donor stem cells (allogeneic stem cell transplant). These complications can be severe and can lead to death. Your healthcare team will monitor you for signs of complications if you have an allogeneic stem cell transplant.

What should I discuss with my healthcare team about pregnancy and nursing before starting treatment?

Tell your healthcare team if you are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during and for at least 5 months after the last dose of OPDIVO.

Talk to your healthcare team about birth control methods that you can use during this time. Tell your healthcare team right away if you become pregnant or think you are pregnant during treatment. You or your healthcare team should contact Bristol-Myers Squibb at
1-800-721-5072 as soon as you become aware of the pregnancy.

Enrolling in a Pregnancy Safety Surveillance Study is encouraged for females who become pregnant during treatment with YERVOY. The purpose of this study is to collect information about your health and the health of your baby. You or your healthcare provider can enroll in the Pregnancy Safety Surveillance Study by calling .

Tell your healthcare team if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of YERVOY.

What should I discuss with my healthcare team before starting treatment?

Talk to your healthcare team about all of your health problems or concerns, including if you:

  • have immune system problems such as autoimmune disease, Crohn’s disease, ulcerative colitis, lupus, or sarcoidosis
  • have had an organ transplant
  • have lung or breathing problems
  • have liver problems
  • have any other medical conditions

Talk to your healthcare team about all the medicines you take, including:

  • prescription medicines
  • over‑the‑counter medicines
  • vitamins
  • herbal supplements

What are the most common side effects?

The most common side effects of OPDIVO when used alone include:

  • feeling tired
  • rash
  • pain in muscles, bones, and joints
  • itchy skin
  • diarrhea
  • nausea
  • weakness
  • cough
  • vomiting
  • shortness of breath
  • constipation
  • decreased appetite
  • back pain
  • upper respiratory tract
    infection
  • fever
  • headache
  • abdominal pain

The most common side effects of OPDIVO when used in combination with YERVOY include:

  • feeling tired
  • rash
  • diarrhea
  • nausea
  • fever
  • pain in muscles, bones, and joints
  • upper respiratory tract infection
  • itching
  • abdominal pain
  • vomiting
  • cough
  • decreased appetite
  • shortness of breath

The most common side effects of YERVOY include:

  • feeling tired
  • diarrhea
  • nausea
  • itching
  • rash
  • vomiting
  • headache
  • weight loss
  • fever
  • decreased appetite
  • difficulty falling or staying asleep

These are not all of the possible side effects. Talk to your healthcare team for more information. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see accompanying U.S. Full Prescribing Information, including Boxed WARNING regarding immune-mediated side effects, and Medication Guide for YERVOY.

Please see accompanying U.S. Full Prescribing Information and Medication Guide for OPDIVO.

Talk to your healthcare team for more information about these medications.

Information provided on this website is not a substitute for talking with your healthcare professional.
Your healthcare professional is the best source of information about your disease.

All individuals depicted are models used for illustrative purposes only.

Bristol-Myers Squibb Corporate Site

Site Map | Legal Notice | Privacy Policy

© 2019 Bristol‑Myers Squibb Company. All rights reserved.

OPDIVO®, YERVOY®, Access Support®, and the related logos are registered trademarks of Bristol-Myers Squibb Company. Adcetris® is a registered trademark of Seattle Genetics, Inc.
Nexavar® is a registered trademark of Bayer.

This site is intended for U.S. residents 18 years of age or older.

1506US1803415-05-01   06/19